Fibromyalgia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Published: November 2011
No. of Pages: 83
Price: $ 3500
GlobalData, the industry analysis specialist, has released its new report, “Fibromyalgia
Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an
essential source of information and analysis on the global FM market. The report identifies
the key trends shaping and driving the global Fibromyalgia Therapeutics market. The report
also provides insights on the prevalent competitive landscape and the emerging players
expected to significantly alter the market positioning of the current market leaders. Most
importantly, the report provides valuable insights on the pipeline products within the global
FM sector. This report is built using data and information sourced from proprietary
databases, primary and secondary research and in-house analysis by GlobalData’s team of
industry experts.
The global market for Fibromyalgia (FM) was valued at $1.7 billion in 2010 and is expected
to grow at a Compound Annual Growth Rate (CAGR) of 4.3% to reach $2.4 billion by 2018.
The restricted growth in the market is due to the unavailability of approved drugs in the EU
and Japan market, expected patent expiry of Cymbalta (2013) and Lyrica (2018) and lack of
newer therapies in late stage FM therapeutics pipeline. Currently, FDA (Food and Drug
Administration) has approved three drugs for the treatment of FM. Lyrica (pregabalin) was
the first drug approved in June 2007 followed by Cymbalta (duloxetine) in June 2008 and
Savella (milnacipran) in January 2009. Marketing authorization of these drugs has been
rejected by EMEA (European Medical Agency) due low effectiveness and high adverse
reactions associated with the drugs. Cymbalta was the first drug to be rejected by EMEA in
2008, followed by Lyrica in 2009 and Savella in 2010. However, increasing prevalence and
diagnosis is expected to drive the future FM therapeutic market.
Scope
The report provides information on the key drivers and challenges of the FM market. Its
scope includes -
- Annualized global FM market revenues data from 2005 to 2010, forecast for eight years to
2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action
being developed and emerging trends. Pipeline candidates fall under major therapeutic
classes such as therapies based on SSRI and GABA agonist calcium channel blocker, sodium
channel blocker, nonrepinephrine reuptake inhibitor, NMDA antagonist.
- Analysis of the current and future competition in the global FM market. Key market
players covered are the Pfizer, Jazz Pharmaceuticals and UCB.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is
independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization,
unmet needs and the implications for the FM therapeutics market.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of
pipeline products and technologies and by identifying the companies with the most robust
pipeline.
- Develop business strategies by understanding the trends shaping and driving the global
FM market.
- Drive revenues by understanding the key trends, innovative products and technologies,
market segments and companies likely to impact the global FM market in future.
- Formulate effective sales and marketing strategies by understanding the competitive
landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective
counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and
segments that present maximum opportunities for consolidations, investments and strategic
partnerships.
- What’s the next big thing in the global FM market landscape? – Identify, understand and
capitalize.
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 7
2 Fibromyalgia Therapeutics: Executive Summary 9
2.1 The Fibromyalgia (FM) Therapeutics Market is Forecast to Show Slow Growth Until 2018
9
2.2 Weak Market Served by Three FDA Approved Products Targeting Symptomatic Relief 10
2.3 Fibromyalgia Therapeutics Market has High Unmet Need 10
2.4 Weak Pipeline with Lack of Promising Molecules 11
2.5 Implications for the Future Market 12
3 Fibromyalgia Therapeutics: Introduction 13
3.1 Overview 13
3.2 Epidemiology 13
3.2.1 Prevalence 13
3.2.2 Co-Morbidities 15
3.2.3 Quality of Life: 15
3.2.4 Economic Burden: 16
3.3 Etiology and Pathophysiology 16
3.4 Symptoms 17
3.5 Diagnosis 18
3.6 Treatment and Management Pattern 20
3.7 Referral Pathway 22
3.8 GlobalData Pipeline Report Guidance 22
4 Fibromyalgia Therapeutics: Market Characterization 24
4.1 Fibromyalgia Therapeutics Market Size (2005 - 2010) - Global 24
4.2 Fibromyalgia Therapeutics Market Forecast (2010 - 2018) - Global 25
4.3 Fibromyalgia Therapeutics Market Size (2005 - 2010): The US 26
4.4 Fibromyalgia Therapeutics Market Forecast (2010-2018): The US 27
4.5 Fibromyalgia Therapeutics Market (2005 - 2010): France 28
4.6 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): France 29
4.7 Fibromyalgia Therapeutics Market (2005 - 2010): Germany 30
4.8 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): Germany 32
4.9 Fibromyalgia Therapeutics Market (2005 - 2010): Italy 33
4.10 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): Italy 34
4.11 Fibromyalgia Therapeutics Market (2005 - 2010): Spain 35
4.12 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): Spain 36
4.13 Fibromyalgia Therapeutics Market (2005 - 2010): The UK 37
4.14 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): The UK 38
4.15 Fibromyalgia Therapeutics Market (2005 - 2010): Japan 39
4.16 Fibromyalgia Therapeutics Market Forecast (2010 - 2018): Japan 40
4.17 Drivers and Barriers for the Fibromyalgia Therapeutics Market 41
4.17.1 Drivers for the Fibromyalgia Therapeutics Market 41
4.17.2 Barriers for the Fibromyalgia Therapeutics Market 41
4.18 Opportunity and Unmet Need Analysis 42
4.19 Key Takeaway 43
5 Fibromyalgia Therapeutics: Competitive Assessment 44
5.1 Overview 44
5.2 Strategic Competitor Assessment 44
5.3 Product Profile for the Major Marketed Products in the Fibromyalgia Therapeutics Market
46
5.3.1 Lyrica (pregabalin) 46
5.3.2 Cymbalta (duloxetine) 48
5.3.3 Savella (milnacipran) 50
6 Fibromyalgia Therapeutics: Pipeline Assessment 52
6.1 Overview 52
6.2 Strategic Pipeline Assessment 52
6.3 Fibromyalgia Therapeutics Pipeline – Pipeline by Phases of Development 52
6.3.1 Fibromyalgia Therapeutics – Filed Pipeline 53
6.3.2 Fibromyalgia Therapeutics – Phase III Pipeline 53
6.3.3 Fibromyalgia Therapeutics – Phase II Pipeline 53
6.3.4 Fibromyalgia Therapeutics – Phase I Pipeline 54
6.4 Fibromyalgia Therapeutics Market – Pipeline by Mechanism of Action 54
6.5 Technology Trends Analytical Framework 55
6.6 Molecule Profile for Drugs under Late Stage Development 57
6.6.1 Lyrica (Pregabalin) 57
6.6.2 JZP-6 (sodium oxybate) 58
7 Fibromyalgia Therapeutics: Clinical Trials Mapping 61
7.1 Clinical Trials by Country (US, EU5 & Japan) 61
7.2 Clinical Trials by Phase 62
7.3 Clinical Trials by Trial Status 63
7.4 Prominent Sponsors 64
7.5 Key Companies Participating in Therapeutics Clinical Trials 65
8 Fibromyalgia Therapeutics: Stategic Assessment 67
8.1 Key Events Impacting on the Future Market 67
8.2 Fibromyalgia Therapeutics: Implications for Future Market Competition 67
9 Fibromyalgia Therapeutics: Future Players 70
9.1 Introduction 70
9.2 Company Profiles 71
9.2.1 Jazz Pharmaceuticals Inc. 71
9.2.2 Pfizer 72
9.2.3 UCB SA 73
9.2.4 Other Companies in the Fibromyalgia Therapeutics Market 74
10 Fibromyalgia Therapeutics: Licensing and Partnership Deals 76
11 Fibromyalgia Therapeutics: Appendix 78
11.1 Market Definitions 78
11.2 Abbreviations 78
11.3 Methodology 79
11.3.1 Coverage 79
11.3.2 Secondary Research 79
11.3.3 Forecasting 80
11.3.4 Primary Research 81
11.3.5 Expert Panel Validation 82
11.4 Contact Us 82
11.5 Disclaimer 82
11.6 Bibliography 83
About Us:
ReportsnReports is an online library of over 100,000+ market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
Contact:
Mr.Priyank
7557 Rambler road,
Suite727,Dallas,TX75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit our Market Research Blog